InflaRx N.V. closed at $1.25 on Nov 6, down 8.12%, 54.6% below its 52-week closing high. Volume of 685.1K shares was 0.62× its 20-day average (below normal).
Split-adjusted performance: -18.6% over one month, -51.7% over six months, +0.4% over one year.
Short interest was 12.7M shares at the Oct 15 settlement, up 3.0% from the prior report (9.2% of float, 21.7 days to cover).
InflaRx NV is a biopharmaceutical company applying proprietary technologies to discover, develop and commercialize potent and specific inhibitors of the complement activation factor known as C5a and its receptor C5aR. With its therapeutic product candidates, vilobelimab and izicopan, the company targets C5a and its receptor C5aR to selectively inhibit the powerful inflammatory response observed in a wide variety of autoimmune and other inflammatory diseases elicited through C5a/C5aR activation.
What is IFRX's market cap?
$183.47M, based on the Nov 6 close of $1.25.
Does InflaRx N.V. pay a dividend?
No regular cash dividend has been paid in the last year.
How much of IFRX is sold short?
12.7M shares, 9.2% of float, as of Oct 15, 2026.
About InflaRx N.V
InflaRx NV is a biopharmaceutical company applying proprietary technologies to discover, develop and commercialize potent and specific inhibitors of the complement activation factor known as C5a and its receptor C5aR. With its therapeutic product candidates, vilobelimab and izicopan, the company targets C5a and its receptor C5aR to selectively inhibit the powerful inflammatory response observed in a wide variety of autoimmune and other inflammatory diseases elicited through C5a/C5aR activation. Its product candidate, GOHIBIC (vilobelimab), is a novel intravenously delivered anti-C5a monoclonal antibody that selectively binds to free C5a and has demonstrated disease-modifying clinical activity and tolerability in multiple clinical settings.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology
